
Quarterly report 2025-Q3
added 11-04-2025
GoodRx Holdings Financial Ratios 2011-2026 | GDRX
Annual Financial Ratios GoodRx Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
118.9 | -367.4 | -99.9 | -444.8 | -56.0 | - | - | - | - | - | - | - | - | - |
P/S |
2.5 | 4.3 | 4.3 | 15.1 | 29.9 | - | - | - | - | - | - | - | - | - |
EPS |
0.0 | -0.0 | -0.1 | -0.1 | -1.1 | 0.2 | 0.1 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
2.16 B | 3.41 B | 3.31 B | 11.1 B | 16.2 B | 1.45 B | 1.48 B | - | - | - | - | - | - | - |
EBITDA per Share |
0.35 | 0.2 | 0.14 | 0.12 | -0.937 | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
227.4 | -62.7 | - | - | - | - | - | - | - | - | - | |||
PEG |
- | 0.1 | - | - | - | - | - | - | - | - | - | |||
P/B |
2.7 | 4.3 | 4.0 | 13.5 | 23.1 | - | - | - | - | - | - | - | - | - |
P/CF |
10.6 | 23.6 | 22.3 | 62.8 | 172.1 | - | - | - | - | - | - | - | - | - |
ROE % |
2.26 | -1.16 | -4.03 | -3.04 | -41.28 | - | - | - | - | - | - | - | - | - |
ROA % |
1.18 | -0.56 | -2.05 | -1.57 | -19.97 | - | - | - | - | - | - | - | - | - |
ROCE % |
9.09 | -3.54 | 0.21 | 1.61 | -19.55 | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.1 | 1.9 | 2.0 | 2.1 | 18.2 | - | - | - | - | - | - | - | - | - |
DSO |
66.7 | 63.4 | 56.0 | 45.7 | 64.5 | - | - | - | - | - | - | - | - | - |
DPO |
190.8 | 147.2 | 98.7 | 108.6 | 127.0 | - | - | - | - | - | - | - | - | - |
Operating Cycle |
66.7 | 63.4 | 56.0 | 45.7 | 64.5 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
-124.1 | -83.7 | -42.7 | -62.8 | -62.5 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios GoodRx Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | 0.04 | 0.03 | 0.01 | 0.02 | - | -0.09 | 0.14 | -0.01 | - | -0.1 | - | 0.03 | - | -0.04 | 0.08 | - | - | -0.21 | 0.08 | 0.08 | - | 0.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.1 | 0.13 | 0.12 | 0.1 | 0.1 | 0.06 | -0.01 | 0.08 | 0.06 | - | - | 0.02 | 0.08 | - | 0.04 | 0.02 | - | - | -0.23 | 0.2 | 0.21 | - | 0.18 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
4.44 | 5.26 | 3.10 | -2.96 | 3.04 | 1.64 | -3.49 | -4.42 | -11.16 | -3.90 | -6.04 | -2.88 | 1.06 | 1.86 | -5.18 | -10.08 | -10.00 | 0.65 | -1.15 | 4.08 | -1.51 | -4.55 | -4.55 | -2.75 | -1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
2.20 | 2.57 | -0.65 | -3.76 | -0.58 | 1.02 | 1.02 | 3.18 | -0.38 | 0.62 | -0.41 | -1.53 | 0.52 | 0.95 | -2.45 | -4.74 | -4.84 | 0.32 | 5.39 | 13.86 | 12.00 | 5.07 | 5.07 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
13.11 | 13.64 | 10.64 | 2.72 | 1.83 | 0.23 | -2.93 | -0.58 | -3.11 | 0.02 | 0.85 | 3.67 | 4.12 | 0.12 | -8.55 | -18.05 | -12.14 | 3.33 | -0.15 | 5.05 | -0.82 | -3.48 | -3.48 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.8 | 1.9 | 2.0 | 2.1 | 1.8 | - | 2.1 | 2.1 | 2.1 | 2.0 | - | 2.1 | 2.0 | 2.1 | 2.1 | 2.1 | 2.0 | 1.9 | 1.9 | 1.9 | 1.9 | 0.5 | 0.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
91.4 | 78.4 | 65.4 | 68.4 | - | - | 62.0 | 57.7 | 57.9 | - | 29.9 | 58.6 | 54.2 | - | 43.4 | 41.7 | 40.7 | - | 44.6 | 50.9 | 40.0 | - | 21.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
184.1 | 139.0 | 94.4 | 114.3 | - | - | 96.8 | 53.6 | 82.2 | - | 44.1 | 75.0 | 112.7 | - | 144.3 | 137.7 | 111.1 | - | 124.5 | 137.6 | 137.5 | - | 105.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
91.4 | 78.4 | 65.4 | 68.4 | - | - | 62.0 | 57.7 | 57.9 | - | 29.9 | 58.6 | 54.2 | - | 43.4 | 41.7 | 40.7 | - | 44.6 | 50.9 | 40.0 | - | 21.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
-92.6 | -60.5 | -29.0 | -46.0 | - | - | -34.8 | 4.1 | -24.3 | - | -14.2 | -16.4 | -58.5 | - | -101.0 | -96.0 | -70.4 | - | -79.9 | -86.7 | -97.6 | - | -83.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company GoodRx Holdings, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Accolade
ACCD
|
- | 0.29 % | $ 206 M | ||
|
Change Healthcare
CHNG
|
- | - | $ 9.03 B | ||
|
Cerner Corporation
CERN
|
- | - | $ 27.9 B | ||
|
American Well Corporation
AMWL
|
$ 5.63 | -2.26 % | $ 90.3 M | ||
|
HealthStream
HSTM
|
$ 21.23 | 1.24 % | $ 645 M | ||
|
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | ||
|
Covetrus
CVET
|
- | - | $ 2.94 B | ||
|
iCAD
ICAD
|
- | - | $ 102 M | ||
|
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | ||
|
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | ||
|
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | ||
|
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | ||
|
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | ||
|
Premier
PINC
|
- | - | $ 2.33 B | ||
|
Omnicell
OMCL
|
$ 34.94 | 1.39 % | $ 1.61 B | ||
|
Phreesia
PHR
|
$ 11.28 | - | $ 615 M | ||
|
OptimizeRx Corporation
OPRX
|
$ 7.18 | 5.9 % | $ 123 M | ||
|
Evolent Health
EVH
|
$ 2.27 | 0.89 % | $ 213 M | ||
|
Schrödinger
SDGR
|
$ 11.4 | -1.47 % | $ 837 M | ||
|
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | ||
|
Teladoc Health
TDOC
|
$ 5.57 | 2.77 % | $ 982 M | ||
|
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | ||
|
SCWorx Corp.
WORX
|
$ 0.13 | 1.5 % | $ 190 K | ||
|
R1 RCM
RCM
|
- | - | $ 3.81 B | ||
|
Akerna Corp.
KERN
|
- | - | $ 161 M | ||
|
Zhongchao
ZCMD
|
$ 1.8 | -0.55 % | $ 9.37 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | ||
|
Health Catalyst
HCAT
|
$ 1.1 | 0.46 % | $ 76.9 M | ||
|
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | ||
|
HealthEquity
HQY
|
$ 82.47 | 0.45 % | $ 7.1 B | ||
|
10x Genomics
TXG
|
$ 20.91 | 5.55 % | $ 2.45 B | ||
|
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | ||
|
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | ||
|
Progyny
PGNY
|
$ 17.75 | -1.66 % | $ 1.52 B | ||
|
So-Young International
SY
|
$ 3.19 | 9.62 % | $ 253 M | ||
|
Veeva Systems
VEEV
|
$ 178.11 | -0.56 % | $ 29.2 B |